Yakujihou Marketing Jimusho Co., Ltd, Tokyo, Japan.
Japan Bio Science Laboratory Co., Ltd, Osaka, Japan.
Int J Food Sci Nutr. 2024 Jun;75(4):426-435. doi: 10.1080/09637486.2024.2334070. Epub 2024 Apr 1.
This randomised, placebo-controlled, double-blind, parallel-group study aimed to determine whether encapsulated Ashitaba chalcone (16 mg comprising 10.1 mg 4-hydroxyderricin and 5.9 mg xanthoangelol) could reduce obesity in 17 men and 25 women with a body mass index (BMI) of 25 to < 30. Participants ingested capsules containing either the chalcone or a placebo daily for 12 weeks. The primary endpoint was changes in visceral fat areas determined by computed tomography (CT) at baseline, and at 8 and 12 weeks later. The primary endpoint, abdominal visceral fat area, was significantly reduced in the chalcone, compared with a placebo group 12 weeks after screening ( < 0.05). The secondary endpoint, waist circumference, was significantly decreased in the chalcone, compared with the placebo group at weeks 8 and 12 ( < 0.05 at week 8; < 0.01 at week 12). Therefore, Ashitaba chalcone has anti-obesity benefits for overweight men and women.
这项随机、安慰剂对照、双盲、平行组研究旨在确定含有 16mg 贯叶连翘查尔酮（其中包含 10.1mg 对羟基二氢血根碱和 5.9mg 黄当归醇）的胶囊是否可以减少 17 名男性和 25 名 BMI 为 25 至 <30 的超重或肥胖女性的肥胖症。参与者每天服用含有查尔酮或安慰剂的胶囊，持续 12 周。主要终点是通过计算机断层扫描（CT）在基线以及 8 周和 12 周后确定的内脏脂肪面积的变化。筛选后 12 周，与安慰剂组相比，查尔酮组的主要终点（内脏脂肪面积）显著减少（<0.05）。次要终点，腰围，在 8 周和 12 周时，与安慰剂组相比，贯叶连翘查尔酮组显著减少（第 8 周时 <0.05；第 12 周时 <0.01）。因此，贯叶连翘查尔酮对超重的男性和女性具有抗肥胖益处。
